Announced Tue, 20 May · 18:12 IST

AUDITED FINANCIAL RESULTS 31.03.2025

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionNegative Operating CashflowResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Gujarat Inject Kerala Limited reported audited standalone results for the quarter and year ended March 31, 2025, with full-year revenue from operations surging to ₹1,904.58 lakh from ₹578.83 lakh in FY24 — a roughly 229% jump. Profit after tax for the year climbed to ₹101.72 lakh from just ₹8.28 lakh, pushing EPS to ₹0.70 from ₹0.07. For Q4 alone, however, revenue dipped to ₹423.71 lakh from ₹541.87 lakh in the year-ago quarter, though PAT improved to ₹7.32 lakh. Statutory auditor M/s. S. Mandawat & Co. issued an unmodified (clean) opinion on the results. The company operates in a single segment — trading of vegetables. Despite the strong reported profit, the cash flow statement shows net cash used in operating activities of ₹(352.20) lakh, and reserves remain in deficit at ₹(462.24) lakh.

Likely market impact

Annual revenue and profit growth look dramatic, but the negative operating cash flow and continued accumulated losses signal weak cash generation and raise questions about earnings quality. Shareholders should view the headline profit numbers cautiously until cash collection improves.